BioCryst reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, NC, Sept. 4, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Compensation Committee of BioCryst's Board of Directors has granted nine newly hired employees stock options to purchase an aggregate of 28,400 shares and restricted stock units (RSUs) for an aggregate of 20,025 shares of BioCryst's common stock. The options and RSUs were granted effective August 30, 2024 as an incentive to each employee entering into employment with BioCryst. The options and RSUs were granted pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.69 per share, which is equal to the closing price of BioCryst's common stock on the grant date. The options and RSUs will vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued employment with the Company. Each stock option has a term of 10 years. The options and RSUs are subject to the terms of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or a restricted stock unit agreement, whichever is applicable at the time of grant.